Related Experiment Video
Updated: Jun 28, 2025
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Tumor-associated macrophages affect the treatment of lung cancer
Zhuchen Yu1, Juntao Zou2, Fei Xu2
1Clinical Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, China.
Abstract:
As one of the most common malignant tumors in the world, lung cancer has limited benefits for patients despite its diverse treatment methods due to factors such as personalized medicine targeting histological type, immune checkpoint expression, and driver gene mutations. The high mortality rate of lung cancer is partly due to the immune-suppressive which limits the effectiveness of anti-cancer drugs and induces tumor cell resistance. The currently widely recognized TAM phenotypes include the anti-tumor M1 and pro-tumor M2 phenotypes. M2 macrophages promote the formation of an immune-suppressive microenvironment and hinder immune cell infiltration, thereby inhibiting activation of the anti-tumor immune system and aiding tumor cells in resisting treatment. Analyzing the relationship between different treatment methods and macrophages in the TME can help us better understand the impact of TAMs on lung cancer and confirm the feasibility of targeted TAM therapy. Targeting TAMs to reduce the M2/M1 ratio and reverse the immune-suppressive microenvironment can improve the clinical efficacy of conventional treatment methods and potentially open up more efficient combination treatment strategies, maximizing the benefit for lung cancer patients.
Insights
Targeting tumor-associated macrophages (TAMs) can overcome lung cancer
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Lung cancer, a prevalent malignancy, faces treatment challenges due to its complex tumor microenvironment (TME) and immune suppression.
- Tumor-associated macrophages (TAMs), particularly the M2 phenotype, promote an immune-suppressive TME, hindering anti-tumor immunity and treatment efficacy.
- Existing lung cancer therapies show limited benefits, partly because of the immune-suppressive TME that fosters drug resistance.
Purpose of the Study:
- To analyze the intricate relationship between lung cancer treatments and TAMs within the TME.
- To confirm the therapeutic potential of targeting TAMs to overcome treatment resistance in lung cancer.
- To explore strategies for modulating TAM phenotypes to enhance anti-cancer immune responses.
Main Methods:
- Review and analysis of existing literature on TAM phenotypes (M1 and M2) in lung cancer.
- Investigation of the role of M2 macrophages in creating an immune-suppressive TME.
- Exploration of the impact of various treatment modalities on TAM populations and function.
Main Results:
- M2 macrophages are identified as key contributors to immune suppression and treatment resistance in lung cancer.
- A high M2/M1 macrophage ratio correlates with a poor anti-tumor immune response.
- Targeting TAMs presents a viable strategy to reverse the immune-suppressive microenvironment.
Conclusions:
- Modulating TAMs, specifically reducing the M2/M1 ratio, can enhance the effectiveness of conventional lung cancer treatments.
- Targeting TAMs offers a promising approach to overcome immune suppression and improve clinical outcomes for lung cancer patients.
- This strategy may pave the way for novel combination therapies to maximize patient benefit.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy